 |
| Adding aprepitant to the anti-nausea drug ondansetron, with or without dexamethasone, effectively prevents chemotherapy-induced nausea and vomiting in children. |
Summary
Final results from a phase III randomized clinical trial show that addition of aprepitant (Emend®) to the anti-nausea drug ondansetron (Zofran®), with or without dexamethasone, is effective for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients. Approximately half of patients in the trial who received both drugs experienced no nausea or related issues in the 5 days following chemotherapy, compared with approximately one-quarter of patients who only received ondansetron.
from Cancer Information - Treatment Prevents Chemotherapy Side Effects for Children with Cancer - National Cancer Institute
0 коммент.